Abliva AB Stock price

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:46:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.1622 SEK +0.75% Intraday chart for Abliva AB +8.71% -33.93%
Sales 2024 * - Sales 2025 * - Capitalization 171M 16M
Net income 2024 * -142M -13.26M Net income 2025 * -157M -14.66M EV / Sales 2024 * -
Net cash position 2024 * 124M 11.58M Net cash position 2025 * 173M 16.15M EV / Sales 2025 * -
P/E ratio 2024 *
-1.25 x
P/E ratio 2025 *
-1.08 x
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.75%
1 week+8.71%
Current month-0.37%
1 month-0.49%
3 months-34.20%
6 months-32.42%
Current year-33.93%
More quotes
1 week
0.15
Extreme 0.149
0.17
1 month
0.14
Extreme 0.14
0.17
Current year
0.14
Extreme 0.14
0.27
1 year
0.14
Extreme 0.14
0.32
3 years
0.14
Extreme 0.14
0.82
5 years
0.14
Extreme 0.14
2.68
10 years
0.14
Extreme 0.14
82.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 21-02-02
Founder 54 00-01-31
Director of Finance/CFO 57 13-11-30
Members of the board TitleAgeSince
Chairman 69 16-04-27
Director/Board Member 49 17-04-26
Founder 54 00-01-31
More insiders
Date Price Change Volume
24-03-28 0.1622 +0.75% 1,049,753
24-03-27 0.161 +4.14% 882,691
24-03-26 0.1546 +3.62% 688,524
24-03-25 0.1492 +0.13% 879,348
24-03-22 0.149 -0.13% 1,052,806

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:46 am EDT

More quotes
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Abliva AB - Nasdaq Stockholm